BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 33582427)

  • 1. Targeted therapy for treatment of patients with classical hairy cell leukemia.
    Moore JE; Delibert K; Baran AM; Evans AG; Liesveld JL; Zent CS
    Leuk Res; 2021 Mar; 102():106522. PubMed ID: 33582427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia.
    Tiacci E; De Carolis L; Simonetti E; Capponi M; Ambrosetti A; Lucia E; Antolino A; Pulsoni A; Ferrari S; Zinzani PL; Ascani S; Perriello VM; Rigacci L; Gaidano G; Della Seta R; Frattarelli N; Falcucci P; Foà R; Visani G; Zaja F; Falini B
    N Engl J Med; 2021 May; 384(19):1810-1823. PubMed ID: 33979489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single agent vemurafenib or rituximab-vemurafenib combination for the treatment of relapsed/refractory hairy cell leukemia, a multicenter experience.
    Yiğit Kaya S; Mutlu YG; Malkan ÜY; Mehtap Ö; Keklik Karadağ F; Korkmaz G; Elverdi T; Saydam G; Özet G; Ar MC; Melek E; Maral S; Kaynar L; Sevindik ÖG
    Leuk Res; 2024 May; 140():107495. PubMed ID: 38599153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitor of BRAF
    Smirnova SY; Al-Radi LS; Moiseeva TN; Gemdzhian EG; Yakutik IA; Julhakyan HL; Novikov VA; Galstyan GM; Sudarikov AB
    Clin Lymphoma Myeloma Leuk; 2021 Jul; 21(7):427-430. PubMed ID: 33811006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab with pentostatin or cladribine: an effective combination treatment for hairy cell leukemia after disease recurrence.
    Else M; Dearden CE; Matutes E; Forconi F; Lauria F; Ahmad H; Kelly S; Liyanage A; Ratnayake V; Shankari J; Whalley I; Catovsky D
    Leuk Lymphoma; 2011 Jun; 52 Suppl 2():75-8. PubMed ID: 21504288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis.
    Else M; Dearden CE; Matutes E; Garcia-Talavera J; Rohatiner AZ; Johnson SA; O'Connor NT; Haynes A; Osuji N; Forconi F; Lauria F; Catovsky D
    Br J Haematol; 2009 Jun; 145(6):733-40. PubMed ID: 19344416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fludarabine and rituximab for relapsed or refractory hairy cell leukemia.
    Gerrie AS; Zypchen LN; Connors JM
    Blood; 2012 Mar; 119(9):1988-91. PubMed ID: 22223825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hairy cell leukemia treated initially with purine analogs: a retrospective study of 107 patients from the Spanish Cooperative Group on Chronic Lymphocytic Leukemia (GELLC).
    López Rubio M; Da Silva C; Loscertales J; Seri C; Baltasar P; Colado E; Pérez Fernández I; Osma M; Gomis F; González M; Jarque I; Vargas M; Monzó E; Monteagudo D; Orts MI; Pardal E; Carbonell F; Perez Calvo C; Garcia-Marco JA
    Leuk Lymphoma; 2014 May; 55(5):1007-12. PubMed ID: 23885799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukemia.
    Else M; Osuji N; Forconi F; Dearden C; Del Giudice I; Matutes E; Wotherspoon A; Lauria F; Catovsky D
    Cancer; 2007 Nov; 110(10):2240-7. PubMed ID: 17886250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How I manage patients with hairy cell leukaemia.
    Thompson PA; Ravandi F
    Br J Haematol; 2017 May; 177(4):543-556. PubMed ID: 28146266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current Therapy and New Directions in the Treatment of Hairy Cell Leukemia: A Review.
    Sarvaria A; Topp Z; Saven A
    JAMA Oncol; 2016 Jan; 2(1):123-9. PubMed ID: 26513168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term follow-up after purine analogue therapy in hairy cell leukaemia.
    Else M; Dearden CE; Catovsky D
    Best Pract Res Clin Haematol; 2015 Dec; 28(4):217-29. PubMed ID: 26614900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized Phase II Study of First-Line Cladribine With Concurrent or Delayed Rituximab in Patients With Hairy Cell Leukemia.
    Chihara D; Arons E; Stetler-Stevenson M; Yuan CM; Wang HW; Zhou H; Raffeld M; Xi L; Steinberg SM; Feurtado J; James L; Wilson W; Braylan RC; Calvo KR; Maric I; Dulau-Florea A; Kreitman RJ
    J Clin Oncol; 2020 May; 38(14):1527-1538. PubMed ID: 32109194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response to the Therapy in Hairy Cell Leukemia: Systematic Review and Meta-Analysis.
    Andrasiak I; Rybka J; Wrobel T
    Clin Lymphoma Myeloma Leuk; 2018 Jun; 18(6):392-399.e3. PubMed ID: 29685423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cutaneous leukocytoclastic vasculitis at diagnosis of hairy cell leukemia successfully treated with vemurafenib and rituximab.
    Robak E; Jesionek-Kupnicka D; Iskierka-Jazdzewska E; Janus A; Robak T
    Leuk Res; 2021 May; 104():106571. PubMed ID: 33831657
    [No Abstract]   [Full Text] [Related]  

  • 16. Hairy Cell Leukaemia.
    Cross M; Dearden C
    Curr Oncol Rep; 2020 Apr; 22(5):42. PubMed ID: 32297104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vemurafenib and Rituximab in Patients with Hairy Cell Leukemia Previously Treated with Moxetumomab Pasudotox.
    Robak T; Janus A; Jamroziak K; Tiacci E; Kreitman RJ
    J Clin Med; 2021 Jun; 10(13):. PubMed ID: 34202156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemoimmunotherapy for hairy cell leukemia.
    Ravandi F
    Best Pract Res Clin Haematol; 2015 Dec; 28(4):230-5. PubMed ID: 26614901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial.
    Chihara D; Kantarjian H; O'Brien S; Jorgensen J; Pierce S; Faderl S; Ferrajoli A; Poku R; Jain P; Thompson P; Brandt M; Luthra R; Burger J; Keating M; Ravandi F
    Br J Haematol; 2016 Sep; 174(5):760-6. PubMed ID: 27301277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
    Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion-Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
    Lancet Oncol; 2018 May; 19(5):603-615. PubMed ID: 29573941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.